A Retrospective Analysis of Safety and Efficacy of XEN 45 Microstent Combined Cataract Surgery in Open-Angle Glaucoma over 24 Months

Subaşı, Sevgi; Yüksel, Nurşen; Özer, Fevzi; Tuğan, Büşra Yılmaz; Pirhan, Dilara

doi:10.4274/tjo.galenos.2020.47629

Cited by 14 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When comparing the results of the current study to those of the XEN45 device, it can be observed that the IOP lowering achieved with XEN63 was consistently greater (see Table 5). Moreover, except for the Hengerer et al study [19], the preoperative IOP of our study was higher than that reported by the other studies [12,[20][21][22][23][24][25][26][27][28][29][30].…”

Section: Discussioncontrasting

confidence: 78%

Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study

Fea

Menchini

Rossi

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Glaucoma surgery has significantly evolved over the last years. This paper aims to evaluate the midterm clinical outcomes of the XEN63 device in a real-world scenario. Methods: A retrospective clinical study was conducted on consecutive patients who underwent an XEN63 implant insertion, either alone or in combination with phacoemulsification. The primary endpoint was the mean intraocular pressure (IOP) at the month 18 visit. Results: Twenty-three eyes (23 patients) were included in the analysis. The preoperative IOP was significantly lowered from 27.0 ± 7.8 mmHg to 14.1 ± 3.4 mmHg at month 18 (p < 0.0001). At month 18, 14 (77.8%) and 11 (61.1%) eyes had an IOP ≤ 16 mmHg and ≤ 14 mmHg, respectively, without ocular hypotensive medication. The mean number of ocular hypotensive medication taken was significantly reduced from 2.3 ± 0.9 drugs at baseline to 1.0 ± 1.4 drugs at month 18 (p = 0.0020). Four (17.4%) eyes had hypotony at postoperative day 1, which was successfully resolved without sequelae. Four (17.4%) eyes underwent a needling procedure and four (17.4%) eyes underwent additional surgeries. Conclusions: The XEN63, either alone or in combination with cataract surgery, significantly lowered the IOP and reduced the need for ocular hypotensive drugs over a period of 18 months.

show abstract

Section: Discussioncontrasting

confidence: 78%

Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study

Fea

Menchini

Rossi

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In most studies, the proportion of IOP decreases was >30%. Only 6 studies reported that IOP decreased by <20% (24,30,31,35,49,66). A common feature was found among these studies, which was that the baseline IOP was at a relatively low level of <22 mmHg.…”

Section: Decreasing Iop and Reducing Antiglaucoma Medicationsmentioning

confidence: 99%

The Outcomes of XEN Gel Stent Implantation: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

PurposeXEN gel stents are used for the treatment of open-angle glaucoma (OAG), including primary and secondary glaucoma that are uncontrolled by previous medical therapy and cases with previous failed surgery. Our aim was to systematically review of the clinical data of currently published ab-interno XEN gel stents with an emphasis on intraocular pressure (IOP), antiglaucoma medication outcomes, and safety profiles.MethodsWe analyzed all of the publications (MEDLINE, EMBASE, Cochrane Library) on the ab-interno XEN gel stent to evaluate the reduction in IOP and antiglaucoma medications following the procedure. The primary outcomes measured for the meta-analysis were reduction in IOP and anti-glaucoma medications. The secondary outcome were adverse events. For each study, we used a random effects analysis model to calculate the mean difference and 95% confidence intervals for the continuous results (reduction in IOP and antiglaucoma medications) using the inverse variance statistical method.ResultsFive hundred twenty-seven articles were checked and 56 studies were found to be relevant with a total of 4,410 eyes. There was a significant reduction in IOP as well as in the number of medications required in patients treated with ab-interno XEN implant either alone or combined with cataract surgery. This new treatment for various types of glaucoma reduced the IOP by 35% to a final average close to 15 mmHg. This reduction was accompanied by a decrease in the number of antiglaucoma medications in all the studies, approximately 2 classes of medication at the price of more needlings. The overall complete success rate was 21.0–70.8% after 2 years using strict criteria originally designed to record success rate in filtration surgery. The incidence of complications vision-threatening was low at <1%.ConclusionsXEN gel stent was effective and safe for primary and secondary OAG. Further studies should be performed to investigate the impact of ethnicity on the success and failure rate after XEN implantation.

show abstract

“…Dentre as complicações, podemos citar sangramento na câmera anterior 19,34 , hipotonia transitória 19,20 , endoftalmite 17 , descolamento de retina 18,20 , bolhas subconjuntivais 18,24 ou diplopia 31 , que podem estar ligadas as técnicas que os profissionais utilizam, posicionamento incorreto do stent 31 ou em decorrência das drogas que precisam ser utilizadas pós procedimento cirúrgico, como colírios a base de corticoides 27,32,36 e antibióticos 32,37,40 .…”

Section: Discussionunclassified

Análise Da Prevalência Do Conhecimentos Dos Riscos E Experimentação De Cigarros Eletrônicos Por Estudantes De Medicina Do Centro Universitário Tocantinense Presidente Antônio Carlos - Unitpac 2022/1

Teixeira¹,

Couto²,

Macambira³

2022

Medicina: Atenção Às Rupturas E Permanências De Um Discurso Científico 2

View full text Add to dashboard Cite

Direitos para esta edição cedidos à Atena Editora pelos autores. Open access publication by Atena Editora Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0). O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

show abstract

A Retrospective Analysis of Safety and Efficacy of XEN 45 Microstent Combined Cataract Surgery in Open-Angle Glaucoma over 24 Months

Cited by 14 publications

References 29 publications

Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study

Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study

The Outcomes of XEN Gel Stent Implantation: A Systematic Review and Meta-Analysis

Análise Da Prevalência Do Conhecimentos Dos Riscos E Experimentação De Cigarros Eletrônicos Por Estudantes De Medicina Do Centro Universitário Tocantinense Presidente Antônio Carlos - Unitpac 2022/1

Contact Info

Product

Resources

About